Viking Therapeutics

Bill Riesner, J.D., M.B.A.

Treatment with Oral VK2735 Results in Significant Weight Loss: The Randomized, Placebo-Controlled, Dose-Finding, VENTURE-Oral Study

VANQUISH-1: Phase 3 Trial with Enrollment of a Diverse Population to Test Efficacy of Subcutaneous VK2735 in Adult Participants with Obesity or Overweight With Weight-Related Comorbidity

Katherine Mercier

Prevalence of Cardiovascular-Kidney-Metabolic Conditions Across Body Mass Index Categories: The Distinct Burden of Severe (Class III) Obesity

Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study